We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Analysis of RNA Carried by Tumor-educated Platelets Yields Valuable Diagnostic Clues

By LabMedica International staff writers
Posted on 15 Nov 2015
Print article
Image: Three-dimensional rendition of human blood platelets (Photo courtesy of Wikimedia Commons).
Image: Three-dimensional rendition of human blood platelets (Photo courtesy of Wikimedia Commons).
Analysis of tumor RNA carried in the afflicted individual's blood platelets may be more useful than other "liquid biopsy" technologies for diagnosing cancer and determining its primary location and potential therapeutic approaches.

Tumor-educated blood platelets (TEPs), which have incorporated molecules shed by tumors, have been implicated as central players in the systemic and local responses to tumor growth, thereby altering their RNA profile.

Investigators at Massachusetts General Hospital (Boston, USA) evaluated the diagnostic potential of TEPs by mRNA sequencing of 283 platelet samples. They reported in the October 29, 2015, online edition of the journal Cancer Cell that after amplifying and sequencing the amount of platelet RNA found in the equivalent of a single drop of blood from each individual, they had identified more than 5,000 different platelet RNAs.

Comparing RNA profiles of healthy donors with those of 228 cancer patients revealed increased levels of nearly 1,500 different RNA molecules and decreased levels of almost 800. Analysis of the levels of around 1,000 RNAs from about 300 individuals with a dedicated algorithm that classified whether not they indicated the presence of cancer did so with 96% percent accuracy. All of the patients with localized tumors and 33 of the 39 with tumors of the central nervous system were accurately diagnosed. Across six different tumor types, the location of the primary tumor was correctly identified with 71% accuracy.

"By combining next-generation-sequencing gene expression profiles of platelet RNA with computational algorithms we developed, we were able to detect the presence of cancer with 96% accuracy," said contributing author Dr. Bakhos Tannous, associate professor of neurology at Massachusetts General Hospital. "Platelet RNA signatures also provide valuable information on the type of tumor present in the body and can guide selection of the most optimal treatment for individual patients.

"We observed that the mRNA profiles of tumor-educated platelets have the sensitivity and specificity to detect cancer, even in early, non-metastasized tumors," said Dr. Tannous. "We are further assessing the potential of TEP-based screening for therapeutic decision making and also investigating how noncancerous diseases may further influence the RNA repertoire of TEPs."

Related Links:
Massachusetts General Hospital


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.